Adapalene
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1996
- First approval year
- 1996
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Adapalene
- Molecular weight
- 412.53
- Structure (SMILES)
- COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
- adapalene
- Adapalene
- adapalene component of cabtreo
- Adapalene component of cabtreo
- adapalene component of epiduo
- Adapalene component of epiduo
- adapalene component of idp 126
- Adapalene component of idp-126
- differin
- Differin
- ada adapalene
- adapalene
- Adapalene
- Adapalene [EP MONOGRAPH]
- adapalene [INN]
- Adapalene [JAN]
- Adapalene [MART.]
- Adapalene [MI]
- Adapalene [ORANGE BOOK]
- Adapalene [USAN]
- ADAPALENE [USP MONOGRAPH]
- ADAPALENE [USP-RS]
- ADAPALENE [VANDF]
- Adapalene [WHO-DD]
- adapalene ep monograph
- adapalene inn
- adapalene jan
- adapalene mart
- adapalene mi
- adapalene orange book
- adapalene usan
- adapalene usp monograph
- adapalene usp rs
- adapalene vandf
- adapalene who dd
And 15 more, listed on the interactive page.
- CAS registry numbers
- 106685-40-9
- ChEMBL ID
- CHEMBL1265
- InChIKey
- LZCDAPDGXCYOEH-UHFFFAOYSA-N
- PubChem compound IDs
- 60164
- RxNorm IDs (RxCUI)
- 60223
- FDA ingredient codes (UNII)
- 1L4806J2QF
- D10AD03
- D10AD53
Sources for recorded values
- Applicant
- GALDERMA LABS LP
- Approval date
- 31 May 1996
- Application number
- NDA020380
- Patents
- 3
- Designations
- 0
- Earliest recorded loss of exclusivity
- 31 May 2028
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Over the counter
- Pharmacology name
- adapalene
- Type
- Synthetic organic
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- topical
- Action
- Agonist
- Action type
- Agonist
- Target
- Retinoic acid receptor-α
- Gene symbol
- RARA
- Protein identifier
- P10276
- Median affinity
- 5.96
- Affinity units
- pKi
- Action
- Agonist
- Action type
- Agonist
- Target
- Retinoic acid receptor-β
- Gene symbol
- RARB
- Protein identifier
- P10826
- Median affinity
- 7.47
- Affinity units
- pKi
- Primary target
- Yes
- Action
- Agonist
- Action type
- Agonist
- Target
- Retinoic acid receptor-γ
- Gene symbol
- RARG
- Protein identifier
- P13631
- Median affinity
- 6.89
- Affinity units
- pKi
- Primary target
- Yes
- Mechanism
- Retinoic acid receptor agonist
- Action type
- Agonist
- Target
- Retinoic acid receptor
- Protein identifier
- P10276
- Mechanism
- Retinoic acid receptor agonist
- Action type
- Agonist
- Target
- Retinoic acid receptor
- Protein identifier
- P10826
- Mechanism
- Retinoic acid receptor agonist
- Action type
- Agonist
- Target
- Retinoic acid receptor
- Protein identifier
- P13631
Open Targets mechanisms
- Mechanism
- Retinoic acid receptor agonist
- Action type
- Agonist
- Target
- Retinoic acid receptor
- Action type
- Agonist
- Gene symbol
- RARB
- Protein identifier
- P10826
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Agonist
- Gene symbol
- RARG
- Protein identifier
- P13631
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Skin Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000701
- Subject identifier
- D012871
- Condition
- Acne Vulgaris
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003894
- Subject identifier
- D000152
- Condition
- Molluscum Contagiosum
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007375
- Subject identifier
- D008976
- Condition identifier
- EFO_0000701
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003894
- Condition identifier
- EFO_0007375
- Highest recorded phase
- 3
- Condition identifier
- EFO_1002023
- Condition identifier
- MONDO_0001795
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005855
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0011438
- Highest recorded phase
- 4
- Condition identifier
- MP_0001845
- Highest recorded phase
- 1
- Event
- abdominal pain
- Reports
- 1
- Reporting signal score
- 10.5624
- Event
- acne
- Reports
- 164
- Reporting signal score
- 628.582
- Event
- acne cystic
- Reports
- 13
- Reporting signal score
- 57.3752
- Event
- acne pustular
- Reports
- 2
- Reporting signal score
- 6.89649
- Event
- acute kidney injury
- Reports
- 1
- Reporting signal score
- 6.80755
- Event
- application site burn
- Reports
- 6
- Reporting signal score
- 16.8731
- Event
- application site dryness
- Reports
- 3
- Reporting signal score
- 9.86573
- Event
- application site erythema
- Reports
- 11
- Reporting signal score
- 21.5942
- Event
- application site exfoliation
- Reports
- 6
- Reporting signal score
- 21.4366
- Event
- application site pruritus
- Reports
- 9
- Reporting signal score
- 18.8253
- Event
- application site rash
- Reports
- 5
- Reporting signal score
- 8.991
- Event
- application site swelling
- Reports
- 4
- Reporting signal score
- 10.4505
- Event
- asthenia
- Reports
- 1
- Reporting signal score
- 15.0777
- Event
- blister
- Reports
- 26
- Reporting signal score
- 35.7358
- Event
- burns second degree
- Reports
- 4
- Reporting signal score
- 11.9814
- Event
- chemical burn
- Reports
- 7
- Reporting signal score
- 34.5231
- Event
- chemical burn of skin
- Reports
- 25
- Reporting signal score
- 153.806
- Event
- cough
- Reports
- 1
- Reporting signal score
- 9.94136
- Event
- cranial nerve paralysis
- Reports
- 2
- Reporting signal score
- 7.15371
- Event
- dermatitis
- Reports
- 33
- Reporting signal score
- 83.8639
- Event
- dermatitis allergic
- Reports
- 12
- Reporting signal score
- 20.4633
- Event
- dermatitis contact
- Reports
- 15
- Reporting signal score
- 35.8743
- Event
- diarrhoea
- Reports
- 1
- Reporting signal score
- 30.0511
- Event
- dizziness
- Reports
- 2
- Reporting signal score
- 18.4688
- Event
- drug interaction
- Reports
- 2
- Reporting signal score
- 7.40177
And 52 more, listed on the interactive page.
- NCT00151541
- NCT00421993
- NCT00422240
- NCT00441415
- NCT00446043
- NCT00469755
- NCT00598832
- NCT00599521
- NCT00660985
- NCT00671749
- NCT00687908
- NCT00688064
- NCT00696449
- NCT00714714
- NCT00757523
- NCT00807014
- NCT00829049
- NCT00883233
- NCT00887484
- NCT00919191
- NCT00926367
- NCT00952523
- NCT01014689
- NCT01106807
- NCT01138735
And 45 more, listed on the interactive page.
- Route
- Topical
- How often
- Once daily
- Apply at nighttime
- Apply to affected areas of the skin
- Use a thin film
- Hydrogen bond acceptors
- 2
- Hydrogen bond donors
- 1
- Polar surface area
- 46.53
- Calculated partition coefficient (ALogP)
- 6.68
- Calculated partition coefficient (XLogP)
- 7.7
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 4
- Heavy atoms
- 31
- Molecular formula
- C28H28O3
- Monoisotopic mass
- 412.20384475
- Natural product
- Yes
- 0168-0424
- 0187-0006
- 0299-5906
- 0299-5918
- 0472-0126
- 0480-3154
- 21922-051
- 21922-052
- 45802-453
- 45802-846
- 45802-853
- 46708-549
- 46708-662
- 49908-118
- 59651-604
- 62332-549
- 62332-662
- 68308-662
- 68308-666
- 68462-301
- 72578-119
- 51672-1364
- 51672-1377
- 51672-1384
- 63629-8607
And 8 more, listed on the interactive page.
- Recorded assays
- 1,065
- Active assays
- 118
- Confirmatory
- Other
- Screening
- Summary
- Anti-Inflammatory Agents, Non-Steroidal
- Dermatologic Agents
Related records
Trials (90)
- "A Comparative Clinical Evaluation of the Efficacy of Topical Adapalene, Benzoyl Peroxide Gel, Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule, and Their Fixed Combination in Mild to Moderate Acne Vulgaris Patients."
- A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris
- A Comparative Study of Adapalene Gel,0.3% Versus Tretinoin Emollient Cream, 0.05% for the Treatment of Photoaging
- A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne
- A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4%
- A Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in the Prevention and Treatment of Senile Purpura
- A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne
- A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris
- A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.
- A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.
- A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris
- A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne Vulgaris
- A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne
- A Treatment for Severe Inflammatory Acne Subjects
- A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris
- Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris
- Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars
- Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage
- Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance
- Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris
Approved for (1)
In development for (2)
- Molluscum contagiosum Phase 3
- Skin disorder Phase 1
Other linked conditions (1)
- Plantar wart